pharm-tablet-production-995x60 pharm-tablet-production-995x60

FEATURED ARTICLES

  • 3 Growth Opportunities For Drug Delivery
    3 Growth Opportunities For Drug Delivery

    Where will tomorrow’s drug delivery opportunities come from? Advances in science and technology are opening the door for innovative treatment options and novel delivery mechanisms. At the same time, the integration of advanced analytics and sensor technologies is enabling the development of drug delivery devices that are smarter, more automated, and more connected than ever before.

More Featured Articles

WHITE PAPERS & CASE STUDIES

  • Improving Suspendibility Of A Water- Insoluble API For Oral Suspension
    Improving Suspendibility Of A Water- Insoluble API For Oral Suspension

    To improve the suspendibility of a water- insoluble active pharmaceutical ingredient (API) in a sorbitol- based reconstitutable powder for oral suspension formulation using two novel excipients Sentry™Polyox™WSR N80, NF (polyethylene oxide) and Avicel CL-611® NF (microcrystalline cellulose/carboxymethylcellulose sodium).

  • Comparative Human <em>in-vivo</em> Study And The Impact Of The Dissolution Rate On Bioequivalence
    Comparative Human in-vivo Study And The Impact Of The Dissolution Rate On Bioequivalence

    Rapid and consistent in-vivo drug dissolution is critical for drug absorption. In-vitro dissolutions tests are used to predict in-vivo disintegration and dissolution properties of drug products. The in-vitro disintegration and dissolution times of tablets and capsules can vary significantly based on their composition and processing.

  • Using QbD For Process Optimization Of A Novel Oral Solid Dosage Form
    Using QbD For Process Optimization Of A Novel Oral Solid Dosage Form

    As stated in the International Conference on Harmonisation Harmonised Tripartite Guidance on Pharmaceutical Development, ICH Q8 (R2), “The aim of pharmaceutical development is to design a quality product and its manufacturing process to consistently deliver the intended performance of the product.”1 Several tools are available as guidance issued by FDA such as “Quality Systems Approach to cGMP Manufacturing”2 that includes ideas such as Quality by Design (QbD) in the development process. This guidance, amongst others, lay the framework for expectations of regulatory reviewers in their examination of client submittal documentation.

  • Modular Facility Design: A Cost-Effective Option In The Post-Blockbuster Drug Era
    Modular Facility Design: A Cost-Effective Option In The Post-Blockbuster Drug Era

    The pharmaceutical industry has undergone a sea of change in recent years as manufacturers have adapted to the end of the era of large-volume production of mass-market blockbuster drugs. With firms now focusing in on subpopulations of patients, there is a need for lean, adaptable facilities that can switch quickly between multiple products in multiple formats. Modular facilities can meet this need. While not a panacea, for the right project characteristics, ‘Modularity in Design’ can deliver significant and quantifiable long-term value.

  • The Effect Of Tablet Porosity On Dissolution
    The Effect Of Tablet Porosity On Dissolution

    Porosity is a characteristic that influences many of the critical quality attributes of finished pharmaceutical products. Porosity can help predict deformation properties during compression, pharmacokinetic behavior within the body, shelf life, moisture penetration, and bioavailability.

  • Excipients: The Unsung Heroes Of Pharmaceuticals
    Excipients: The Unsung Heroes Of Pharmaceuticals

    <p>Excipients are often described as inactive ingredients that assist in the delivery and processing of the active pharmaceutical ingredients. Although this is true, excipients have a much larger influence on final product performance than the term &ldquo;inactive ingredient&rdquo; suggests. In fact, choosing the right excipients is a key determinant of the quality and functionality of a pharmaceutical product.</p>

     

More White Papers & Case Studies

PRODUCTS & SERVICES

R&D Tablet Coater: SolidLab 2 R&D Tablet Coater: SolidLab 2

Easy scale-up
The Solidlab 2 laboratory machine handles batch sizes from 0.25 to 12 kilograms in laboratory scale. The different modules use a common periphery and are constructed like full scale production machines. This enables an easy scale-up of all production parameters.

Laboratory Tablet Coater: SolidLab 1 Laboratory Tablet Coater: SolidLab 1

The Solidlab 1 laboratory machine processes batch sizes from 0.05 to 1 kilograms and is the equivalent for the highest performance in the smallest space. The plant supports you in developing your products and in examining your recipes. All important parameters and results are recorded by the software, and changes are documented. This makes the Solidlab 1 the ideal solution for your feasibility studies.

Large Scale Tablet Coating System: XL Cota 750 Large Scale Tablet Coating System: XL Cota 750

The Manesty XL Cota 750 is designed for larger batch production and has the same proven benefits in operation as the smaller 150 and 350 sizes. Dependability and reliability are key attributes for this size of batch and with a proven installed base, the XL Cota 750 is again ideally suited for all tablet coating requirements. With segmented drum technology the efficient coating of pellets and seed API’s is also possible.
 

Pharmaceutical Tablet Coating Equipment: XL Cota 350 Pharmaceutical Tablet Coating Equipment: XL Cota 350

The Manesty XL Cota is used as a model against which all other manufacturer’s units are compared* and is the Pharmaceutical Industry’s tablet coating standard, Benefitting from a proven installed world wide base it is ideally suited for all tablet coating requirements. With segmented drum technology the efficient coating of pellets and seed API’s is also possible.

Manesty Pharmaceutical Tablet Coater: XL Cota Manesty Pharmaceutical Tablet Coater: XL Cota

The Manesty XL Cota is used as a model against which all other manufacturer’s units are compared* and is the Pharmaceutical Industry’s tablet coating standard, Benefitting from a proven installed world wide base it is ideally suited for all tablet coating requirements. With segmented drum technology the efficient coating of pellets and seed API’s is also possible.

Manesty Premier Pharma Tablet Coater 900 Manesty Premier Pharma Tablet Coater 900

Manesty are true innovators in the development of side vented pan coating technology. The Premier 900 coating system is for large sized batches up to 900 litres. Capable of working with aqueous and organic film and sugar solutions, it is ideally suited for all tablet coating requirements. With segmented drum technology the efficient coating of pellets and seed API’s is also proven.

Tablet Coater: Premier Coater 500 Tablet Coater: Premier Coater 500

Manesty are true innovators in the development of side vented pan coating technology. The Premier 500 coating system is for large sized batches up to 600 litres. Capable of working with aqueous and organic film and sugar solutions, it is ideally suited for all tablet coating requirements. With segmented drum technology the efficient coating of pellets and seed API’s is also proven.

Tablet Coating System: Manesty Premier Coater 200 Tablet Coating System: Manesty Premier Coater 200

Manesty are true innovators in the development of side vented pan coating technology. The Premier 200 coating system is for medium sized batches up to 225 litres. Capable of working with aqueous and organic film and sugar solutions, it is ideally suited for all tablet coating requirements. With segmented drum technology the efficient coating of pellets and seed API’s is also proven.

More Products & Services